Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute LeukemiaChildren’s Hospital Medical Center, Cincinnati
ClinicalTrials.gov Identifier: NCT03825289
Venetoclax PubChem CID: 11707110
Vyxeos PubChem CID: 11707110
Investigators at Children’s Hospital Medical Center, Cincinnati, have opened a Phase I clinical trial to study the safety and tolerability of combining venetoclax (VENCLEXTA®, AbbVie) with VYXEOS® (CPX-351, daunorubicin and cytarabine, Jazz Pharmaceuticals) in pediatric and young adult patients with acute leukemia that has come back or has not responded to treatment.
See complete details, including study location(s), eligibility criteria, contact information, and study results (when available) at ClinicalTrials.gov.
Send email to email@example.com for information about submitting qualified clinical trials for sponsored posts on this blog.
The information on my blog is not intended as a substitute for medical professional help or advice but is to be used only as an aid in understanding current medical knowledge. A physician should always be consulted for any health problem or medical condition.